High Court · Decided 7 April 2026
Zyfas Medical Co (sued as a firm) v Millen nium Pharmaceuticals, Inc and another
Feedback & support[2026] SGHCR 9 · Case no. Bill of Costs No 11 of 2026 (Summons No 503 of 2026) · 9 paragraphs
✱ What happened, in plain English
There is no plain-English summary of this judgment yet.
Ask about this judgment →Grounds of decision
Official text from eLitigation
- [2]
[2] Brief reasons were provided when I dismissed the application. An appeal has since been filed against my decision, and I now set out my full written grounds of decision.
Facts
- [6]
[6] On 11 February 2026, the Respondents filed HC/SUM 503/2026 (“SUM 503”) for an order that the hearing of BC 11 be fixed only after the conclusion of the assessment of damages proceedings in Suit 817 (and any appeals arising). In the Respondents’ affidavit in support of SUM 503, the Respondents stated that the application was being brought under O 4 r 1 of the Rules of Court (2014 Rev Ed) (“ROC 2014”). The Respondents referred to the ROC 2014 because the underlying action (Suit 817) is governed by the ROC 2014.
- [7]
[7] The assessment of damages proceedings that the Respondents were referring to is an inquiry into the damages, if any, that the Respondents are to pay Zyfas to compensate Zyfas for the alleged loss that it suffered from an interim injunction that was ordered in Suit 817 on 2 April 2020. That injunction restrained Zyfas from “performing any of the act(s) for which registration of [Zyfas’s product] [had] been obtained” until the conclusion of Suit 817: see Millennium Pharmaceuticals at [19]. The interim injunction was eventually discharged at the close of the trial on 27 October 2021 after the parties consented to the discharge: see Millennium Pharmaceuticals at [21].
- [8]
[8] The assessment of damages proceedings were scheduled to be heard in a trial commencing in late April 2026.
The parties’ submissions
Analysis and decision
- [12]
[12] I dismissed SUM 503 for the following reasons.
- [13]
[13] The assessment of damages proceedings concerned an inquiry into the damage that Zyfas had suffered from the interim injunction ordered in Suit 817 restraining Zyfas from performing any acts for which the registration of its product had been obtained. The assessment of damages did not pertain to the liability of the parties in respect of the substantive claims made in Suit 817, which concerned the validity and scope of certain patents, and whether the patents were infringed.
- [14]
[14] The Court of Appeal’s observation in Lin Jian Wei at [84] did not apply to the present case. I set out the Court of Appeal’s observation in Lin Jian Wei at [84] here for reference:
- [18]
[18] That was not the context in the present case. The substantive claims in Suit 817 had been fully resolved in favour of Zyfas, and there were no damages to be assessed from those substantive claims which were dismissed. Importantly, the assessment of damages proceedings did not arise from any of the substantive claims made in Suit 817. Rather, they concerned damages that ought to be awarded in respect of an unrelated interlocutory process – namely, the granting of an interim injunction that was later discharged. Accordingly, the amount, if any, that might be awarded through that inquiry would not have been a reflection of the amount that was at stake in the liability trial in Suit 817. What was at stake in the liability trial was the validity of certain patents and whether there had been infringement, not the alleged damage that was suffered on account of the interim injunction.
Costs
(a) I did not think that the range in Appendix G to the Supreme Court Practice Directions at Part II.B, para 11 should be applied. The ranges set out in that paragraph were for specific types of stays (namely, stays in favour of arbitration, on account of forum non conveniens and pending appeal). SUM 503 was an application to defer the hearing of an assessment of costs proceeding. The principles that I had to apply were not similar to the principles that would be applied in those three types of stay applications.
(b) I therefore had regard to the range in Appendix G, Part II.A, para 2 for contested general applications. Given the lack of complexity of the arguments made and the relatively short duration of the oral hearing, I found it appropriate to have regard to the range for applications on a normal list lasting 45 minutes or longer, and not the special date range. The range for a normal list matter lasting 45 minutes or longer is $4,000 to $11,000 excluding disbursements.
(c) I found that the costs award should be at the lower end of the range in view of the limited nature of the application. The case turned essentially on the interpretation of two Court of Appeal authorities. The facts were not disputed and the submissions were concise. Having regard to these circumstances and the amount of disbursements incurred, a costs award of $4,200 was appropriate and I so ordered.
Conclusion
- [21]
[21] For the reasons set out above, I dismissed the stay application.